<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03877679</url>
  </required_header>
  <id_info>
    <org_study_id>OMED2:5:1</org_study_id>
    <nct_id>NCT03877679</nct_id>
  </id_info>
  <brief_title>The Effect of Topical Curcumin Versus Topical Corticosteroid on Management of Oral Lichen Planus Patients</brief_title>
  <official_title>The Effect of Topical Curcumin Versus Topical Corticosteroid on Pain, Clinical Parameters and Salivary Level of IL-33 in Oral Lichen Planus Patients: A Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduce a new anti-inflammatory and antioxidant paste preparation (curcumin paste) in the
      management of Oral lichen planus.

        -  Assess the efficacy of this preparation on pain, clinical parameter and the level of
           IL-33 in saliva.

        -  Compare the outcome of new preparation with the gold standard treatment
           (corticosteroids).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two groups will be prepared then decision of which one take curcumin paste will be selected
      according to randomized numbers in a sequentially numbered, opaque, sealed envelope

      1 group will take topical corticosteroid and 1 will take curcumin paste then IL-33 level in
      saliva will be measured at the base line and at the end of 4th week pain and clinical
      parameters will be measured at 2nd and 4th week
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcome assessor (CS) and statistician</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>4 weeks</time_frame>
    <description>measured by Visual Analog Scale (VAS) 0 = no pain 10= severe pain 0= no pain 10= pain severe pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical sign score</measure>
    <time_frame>Baseline , 2nd week and 4th week</time_frame>
    <description>measured by Thongprasom from score 0 to 5 0= only white lesion 5=area of erosion more than 2 cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-33 level in saliva</measure>
    <time_frame>base line and 4th week</time_frame>
    <description>by ELISA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Oral Lichen Planus</condition>
  <arm_group>
    <arm_group_label>turmeric paste</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical curcumin gel (a mixture of curcumin powder and vegetable glycerin base in a ratio of 1:8 by weight) Mix with 85ml carbapol gel (125ml H2O + 0.5g carbapol + triethanolamine 3 drops) prepared in the Faculty of pharmacy-Cairo University traumeric extracted from Curcuma plant, it has anti-inflammatory, antioxidative and antineoplastic properties ((Nosratzehi et al., 2018), The curcumin is safe even in high doses, Since oxidative stress may play a role in pathophysiology of OLP, and by noting that OLP is a chronic inflammatory disease, the herbs which have both anti-inflammatory and antioxidant properties may efficiently control OLP (Kia et al., 2015).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcenolone in orabase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Triamcenolone + na ploycarboxylate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone</intervention_name>
    <description>Triamcenolone +napolycarboxylate</description>
    <arm_group_label>Triamcenolone in orabase</arm_group_label>
    <other_name>Triamcenolone in orabase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Turmeric paste</intervention_name>
    <description>Topical turmeric paste (a mixture of curcumin powder and vegetable glycerin base in a ratio of 1:8 by weight) Mix with 85ml carbapol gel (125ml H2O + 0.5g carbapol + triethanolamine 3 drops) prepared in the Faculty of pharmacy-Cairo University</description>
    <arm_group_label>turmeric paste</arm_group_label>
    <other_name>Curcumin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who will be clinically diagnosed as having atrophic &amp;/or erosive oral lichen
             planus.

          -  Patients with controlled diabetes and/or controlled hypertension will be included in
             the study.

          -  Patients with no history of taking corticosteroids for the last 6 months

          -  Patients who agrees to take medication.

        Exclusion Criteria:

          -  Pregnant and lactating ladies.

          -  Patients with history of topical steroids during last 2 months &amp; systemic steroids
             during last 6 months.

          -  Patients with recent dental filling associated with the lesion or associated with
             recent drug administration.

          -  Patient with uncontrolled diabetes, uncontrolled hypertension, or those with positive
             HCV ab or HBs Ag.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med. 2003 Feb;9(1):161-8. Review.</citation>
    <PMID>12676044</PMID>
  </reference>
  <reference>
    <citation>Greenberg G, Glick M. Burket's Oral Medicine: Diagnosis and Treatment. Hamilton, Ontario, BC Decker, 11th ed., 2008:90-1</citation>
  </reference>
  <reference>
    <citation>Nosratzehi T, Arbabi-Kalati F, Hamishehkar H, Bagheri S. Comparison of the Effects of Curcumin Mucoadhesive Paste and Local Corticosteroid on the Treatment of Erosive Oral Lichen Planus Lesions. J Natl Med Assoc. 2018 Feb;110(1):92-97. doi: 10.1016/j.jnma.2017.01.011. Epub 2017 May 11.</citation>
    <PMID>29510851</PMID>
  </reference>
  <results_reference>
    <citation>Chainani-Wu N, Silverman S Jr, Reingold A, Bostrom A, Mc Culloch C, Lozada-Nur F, Weintraub J. A randomized, placebo-controlled, double-blind clinical trial of curcuminoids in oral lichen planus. Phytomedicine. 2007 Aug;14(7-8):437-46. Epub 2007 Jul 2.</citation>
    <PMID>17604143</PMID>
  </results_reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>September 24, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>March 14, 2019</last_update_submitted>
  <last_update_submitted_qc>March 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Mohamed salah abd-elhameed</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>oral lichen planus</keyword>
  <keyword>curcumin</keyword>
  <keyword>IL-33</keyword>
  <keyword>corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lichen Planus, Oral</mesh_term>
    <mesh_term>Lichen Planus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All authors of this trial will have access to the final trial dataset.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>after study completion</ipd_time_frame>
    <ipd_access_criteria>pubmed</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

